Mutant analysis by polymerase chain reaction and restriction enzyme cleavage (MAPREC) was used to study sequence heterogeneity and stability in attenuated poliovirus type 3 at positions in which the vaccine virus differs from its wild-type progenitor. Of seven genomic positions tested, only two (positions 472 Sabin oral poliovirus vaccine (OPV) consists of live attenuated viruses of three serotypes. These viruses replicate in the intestinal tracts of vaccinees, inducing long-lasting immunity but unlike wild-type strains, they cause no disease. According to the World Health Organization (WHO) requirements for OPV (9), the neurovirulence safety of the vaccine is tested by intraspinal inoculation of monkeys with each manufactured vaccine lot along with the homotypic reference lot, followed by 17 to 22 days of observation for neurological signs and necropsy. Histologic assessment of specific lesions in the monkeys central nervous systems allows a comparison of the degree of neurovirulence of a vaccine lot with that of the reference lot. For type 3 virus, the test requires at least 20 monkeys for each vaccine and reference lot.
Sabin oral poliovirus vaccine (OPV) consists of live attenuated viruses of three serotypes. These viruses replicate in the intestinal tracts of vaccinees, inducing long-lasting immunity but unlike wild-type strains, they cause no disease. According to the World Health Organization (WHO) requirements for OPV (9) , the neurovirulence safety of the vaccine is tested by intraspinal inoculation of monkeys with each manufactured vaccine lot along with the homotypic reference lot, followed by 17 to 22 days of observation for neurological signs and necropsy. Histologic assessment of specific lesions in the monkeys central nervous systems allows a comparison of the degree of neurovirulence of a vaccine lot with that of the reference lot. For type 3 virus, the test requires at least 20 monkeys for each vaccine and reference lot.
Using a new sensitive method for quantitation of base substitutions in viral RNA, we recently found that live poliovirus type 3 vaccines contain varying proportions of the virus with altered nucleotide sequences. A higher abundance of reversions at position 472 of the 5' noncoding region correlates with increased neurovirulence in monkeys (1) . Therefore, we proposed that the molecular procedure for quantitation of these revertants could be used as a supplement to the monkey test.
We also showed that these revertants rapidly accumulate in the vaccine in the course of cell culture passage (1) . In addition to position 472, several other positions were shown to differ in wild-type 3 Leon/37 virus and its attenuated derivative Leon 12a1b strain (4) (5) (6) . We asked whether these other mutations contribute to the instability of the poliovirus genome and the increased neurovirulence of some vaccine lots. To answer this question, we designed quantitative assays for mutations at positions of the genome at which the attenuated poliovirus type 3 strain differs from the wild-type progenitor. In this communication, we present the data showing that, with the exception of positions 472 and 2493, all positions remain stable. We also present evidence that of these two variable sites in the virus genome, only position * Corresponding author.
472 is related to neurovirulence in monkeys, while position 2493 has no apparent influence on the attenuated phenotype of the virus.
MATERIALS AND METHODS
Viruses used. Sabin Original (SO) and RNA-plaque-purified SO (RSO) derived vaccines were studied by analyzing RNA extracted directly from vaccine lots. Wild-type Leon/37 preparations were obtained from the American Type Culture Collection (ATCC) (VR-62, VR-63, and VR-1004) and from 0. Kew (Centers for Disease Control, Atlanta, Ga.). Wild-type Fox Wy-3 and attenuated Fox WM-3 strains were obtained from ATCC (VR-193 and VR-300), and a wild-type Saukett strain was given to us by P. Albrecht (Food and Drug Administration-Center for Biologics Evaluation and Research, Bethesda, Md.). The revertant type 3 strain DM Pg35aP-396 was a gift from P. Minor (National Institute for Biological Standards and Control, London, United Kingdom). A recombinant plasmid, pT7/ Leon, containing the complete copy of Sabin poliovirus type 3 was kindly provided by J. Almond (University of Reading, Reading, United Kingdom).
Determination of the abundance of specific mutations. Determination of the abundance of specific mutations at different positions of the poliovirus genome was performed as previously described (1) . In brief, this mutant analysis by polymerase chain reaction (PCR) and restriction enzyme cleavage method includes (i) synthesis of viral cDNA with reverse transcriptase and random primer, (ii) PCR amplification of a specific region with synthetic primers modified to create restriction enzyme recognition sites, and (iii) cutting of PCR product with restriction enzymes and quantitative analysis of cleavage products by gel electrophoresis. The method allows one to quantitate sequence heterogeneity at specific positions of the genome at a level above 0.1%. (5) have found that type 3 vaccines contain C and not U at position 2493. Three of these substitutions are located in untranslated regions, and of nine substitutions in the coding region, only four cause amino acid changes in viral proteins, namely, position 2034 in VP3 and positions 2493, 3333, and 3464 in VP1. We decided to study the stability of these four positions along with the stability of two positions in the 5' noncoding region and position 6061, at which a discrepancy between two published sequences occurred (4, 6) . By using the highly sensitive quantitative mutant analysis by PCR and restriction enzyme cleavage method (1), we determined the sequence heterogeneity at these positions in several vaccine lots made from SO or RSO seeds. Higher-level passages of these strains, as well as some wild-type strains and a cDNA-derived clone of poliovirus type 3, were also tested to study the stability of these positions.
Analysis of position 6061 showed that all vaccines, as well as experimental high-level passage preparations and all wild-type strains, including Leon/37, Fox, and Saukett, contain U, which corresponds to the sequence published by Toyoda et al. (6) . The only sample that showed C at position 6061 (6061-C) was the recombinant plasmid pT7/Leon containing the complete cDNA of poliovirus type 3 (results not shown). No sequence heterogeneity was detected at this position, and the discrepancy in two published sequences may be the result of a cDNA cloning procedure described in reference 4. Anyway, the mutation at position 6061 is silent and does not change the amino acid sequences of viral proteins.
No sequence heterogeneity was observed at positions 220, 2034, and 3464 in either vaccine lots, high-level passages, or wild-type strains (data not shown). The homogeneity of these positions in higher-level passages of the vaccine virus indicates that they remain stable and thus do not contribute to the increased neurovirulence of some vaccine lots. Some heterogeneity was detected at position 3333 in two Fox strains and in the Saukett strain of poliovirus type 3 but not in the wild-type or attenuated Leon strains (Fig. 1. 220, 2034, 3333 , and 3464 showed that the RNA sequence of the last virus, VR-1004, is not consistent with the sequences of other Leon strains but is similar to the sequence of the Sabin strain. At position 2493, VR-1004 has U, which is characteristic of the wild-type strains and of the Sabin strain at a passage level higher than SO+3. At position 472, VR-1004 has ca. 20% C, which is also characteristic of higher-level passages of the Sabin strain. Thus, although we did not sequence the entire genome of this strain, the data for positions that distinguish the Sabin strain from its progenitor suggest that ATCC VR-1004 represents a higher-level passage of the Sabin vaccine strain.
Mutation at position 472 has long been considered a major determinant of attenuation (2). This conclusion was based on the isolation and analysis of neurovirulence of revertant strains, which were presumed to contain only a single base substitution at position 472. However, analysis shows that these revertants contain two base substitutions, at positions 472 and 2493. Thus, it is important to reevaluate the influence of each of these mutations on the neurovirulence of poliovirus type 3. We analyzed several virus preparations containing various amounts of both 472-C and 2493-U. The preparations included commercial vaccine lots, various passages of the Sabin strain cultured under conditions favoring selection of revertants, and clones obtained by plaque purification with subsequent sequence characterization. All preparations were tested for the abundance of reversions at positions 472 and 2493 and inoculated intraspinally in rhesus monkeys according to the WHO procedure. Figure 4A shows the results of the monkey neurovirulence lack of the apparent influence of 2493-U abundance on the neurovirulence of the virus in monkeys is also demonstrated by the results of analysis of clone Llll, which was obtained by plaque purification from the ATCC VR-1004 virus (Fig.  4) . At all genome positions differentiating wild-type and attenuated strains, this clone was found to contain sequences characteristic of an attenuated Sabin strain. Quantitative sequence characterization showed that this clone contained no detectable reversions at position 472 and 100% reversions at position 2493 and showed the lowest histologic lesion score.
DISCUSSION
Because of a high mutation rate, RNA viruses cannot be considered a homogenous population. Rather, they are quasispecies consisting of a population of viral particles containing RNA with slightly different nucleotide sequences. Some of these sequence variants are not viable and contribute to the high ratio of physical to infectious particles, while others are selectively neutral and persist in the population. Under certain growth conditions, they may provide some benefit to the virus and be selected. To what extent can this sequence heterogeneity influence important biological properties of the virus such as neurovirulence?
Recently we demonstrated that the presence of 472-C revertants at a level as low as 1% predicts the failure of the vaccine in the monkey neurovirulence test (1) . Thus, the presence of a small fraction of mutants in the virus population should be studied before any conclusions about the relationship between the genomic sequence of the virus and its biological properties are drawn.
In this communication, we present the results of a study of the genetic stability of live poliovirus vaccine and the sequence variability of selected wild-type strains of poliovirus type 3. We studied positions in the virus genome at which the attenuated Sabin strain differs essentially from its wild-type Leon/37 progenitor. Initially, the sequences of both attenuated and wild-type poliovirus were determined with cDNA clones, which allowed identification of 10 base substitutions between these strains. Recently, direct RNA sequencing (5) 
